作者：侯文皓、邵毅、汪成建、石云飞、侯蕾 全球灯塔网络倡议代表了当今全球制造业智能制造和数字化的最高水平。入选的"灯塔工厂"是具有榜样 意义的"数字化制造"和"工业4.0"示范者，也受到国家和地方层面对于智能制造升级和高质量发展的政 策鼓励和支持。 纵览近几年认证成功的灯塔工厂，其数字化用例类型和部署体现出三个新趋势： 分析式人工智能和生成式人工智能，在灯塔工厂数字化用例中的比重更加显著且贯穿价值链各个环节， 包括资产管理、资源管理、质量管理、劳动力赋能、产品开发、综合供应链规划和采购等，实现了异于 以往数字化用例的更高价值创造。 3 内外兼修，加快部署 对外，灯塔工厂在建设过程中不断学习其它工厂的成功经验, 站在行业经验的基础上取长补短；向内： 大幅提升数字化和人工智能解决方案的部署能力（包括数字化用例的内部主导开发已经占到更高比 例），打造企业内部数字化转型长期落地的实力。 1 "强者更强" 对于已经拥有"灯塔"的企业来说，通过其生产运营网络的规模化设计和体系化能力，其新的"灯塔"能以 极快速度和规模部署新的数字化用例。 2 人工智能（AI)加持 聚光灯下：全球医药行业灯塔工厂在中国 目前全球灯塔网络共有 ...

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. has received a debt waiver from nine bondholders, which significantly impacts its financial structure and ongoing restructuring efforts [1][2][3] Debt Waiver Details - The company has entered into a debt waiver agreement with nine bondholders, which includes a total waiver of 1.1 billion yuan in principal and all accrued interest and penalties, amounting to a total of 2.66 billion yuan [20][21] - The debt waiver is unconditional, irrevocable, and does not require any further internal approval processes [6][13][21] Financial Position - As of the waiver date, the company had outstanding debts of 294.64 million yuan in principal, 93.64 million yuan in interest, and 62.62 million yuan in penalties [6][7] - Following the debt waiver, the remaining debts will be 184.64 million yuan in principal, with no remaining interest or penalties [6][7] Fund Management and Relationships - The nine bondholders are managed by five fund management companies, which have confirmed that they have no relationships with the company, its controlling shareholders, or its executives [4][5][12] - The fund management companies have followed proper internal decision-making procedures regarding the debt waiver [5][12] Restructuring Process - The company is currently in a pre-restructuring phase, with the debt waiver not being a prerequisite for the restructuring process [13][20] - The restructuring efforts have led to a positive shift in the company's net assets, moving from negative to positive [20][22] Asset Management - The company has sold a low-efficiency asset, "Taihu Star," for 64.69 million yuan, which has improved its cash flow and reduced operational pressure [20][21] - The asset sale and debt waiver are part of a broader strategy to optimize the company's financial structure and improve operational capabilities [20][22]

关于深圳证券交易所 对湖南景峰医药股份有限公司 有关财务问题的专项说明回复 大信备字2025第 1-01535 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 WUYIGE Certified Public Accountants.LLP 电话 Telephone：+86（10）82330558 北京市海淀区知春路 1 号 Room 2206 22/F, Xueyuan International Tower 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 学院国际大厦 22 层 2206 No.1 Zhichun Road, Haidian Dist. 邮编 100083 Beijing, China, 100083 关于深圳证券交易所对湖南景峰医药股份有限公司 有关财务问题的专项说明回复 大信备字2025第 1-01535 号 深圳证券交易所公司管理部： 根据贵所于 2025 年 5 月 7 日下发的《关于对湖南景峰医药股份有限公司 2024 年年报 ...

近日，在南京江北新区一家企业的现代化车间里，维修工程师王孟骥正带领团队调试一台工业机器 人。面对设备突发故障，他迅速定位问题，熟练地更换零件，整个过程一气呵成。"两年前，我们遇到 这种情况只能等外援，现在自己就能解决！"王孟骥感慨。 这一变化，正是南京职业技能培训与产业升级深度融合的生动写照。近年来，南京通过精准施策、 创新培训模式，为稳就业、促发展注入强劲动能。 "一企一策"激活产业动能 2024年，南京工艺装备制造股份有限公司申报了"滚动功能部件智能生产线运维人员培训"项目，在 政府补贴支持下，50名一线技术人员接受了196课时的智能生产线滚动元件选型及加工编程技巧、机械 手调试与维保、智能制造电气调试维修等课程培训。培训结束后，项目团队结合所学理论在实践中进行 一系列技术改造，将产线换型效率提高了90%，产量增加20%，如今，参培人员成为一支高技能、高 技术的复合型人才队伍，为智能产线运行提供了坚实保障。 这样的故事在南京还有很多。自2021年起，南京试点"一企一策、一项一价"项目制培训模式，企业 根据实际需求自主设计课程，政府按成效给予补贴。例如，中船鹏力公司的"全固态高分辨力海洋探测 雷达技术培训" ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20250508 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称及 人员姓名 通过线上参与本次网上业绩说明会的广大投资者 时间 2025 年 5 月 8 日 15:00～17:00 地点 上海证券报·中国证券网 https://roadshow.cnstock.com/ 上市公司接待人 员姓名 1、董事长兼总裁：方正先生 2、董事兼副总裁兼董事会秘书：晁虎先生 3、董事兼财务总监：徐海智先生 4、独立董事：许小明女士 投资者关系活动 主要内容介绍 1.公司 2024 年营收创新高，实现扭亏为盈。作为国内知 名的口服固体制剂智能工厂整体解决方案供应商，公司有何特 别优势？ 答：你好，公司作为国内知名的口服固体制剂智能工厂整 体解决方案供应商，优势较为明显，具体如下： 1、公司积累了以优质制药企业为主的大量客户资源，覆 盖我国除台湾、澳门以外的其他所有地区，并且延伸至全球 50 多个国家。 2、公司部分产品基本可以替代进口产 ...

Core Viewpoint - In April 2025, Hunan Jingfeng Pharmaceutical Co., Ltd. released its 2024 annual report, revealing significant changes in key financial indicators such as revenue, net profit, and cash flow, indicating potential operational challenges and risks for investors [1] Financial Performance Summary - **Revenue**: The company reported a revenue of 416,031,777.19 yuan in 2024, a decrease of 36.67% from 656,893,837.84 yuan in 2023. The pharmaceutical business accounted for 94.05% of total revenue, declining by 37.86% [2] - **Net Profit**: The net profit attributable to shareholders was 152,304,308.31 yuan, a turnaround from a loss of 236,100,444.69 yuan in 2023. However, the net profit excluding non-recurring items was -76,117,930.25 yuan, indicating weak core business profitability [3] - **Earnings Per Share**: Basic earnings per share improved to 0.1731 yuan from -0.2684 yuan in 2023, while the diluted earnings per share excluding non-recurring items was -0.0865 yuan, highlighting the disparity in earnings quality [4] Expense Analysis - **Sales Expenses**: Sales expenses decreased by 60.51% to 137,032,632.93 yuan from 347,051,196.83 yuan in 2023, potentially impacting market promotion and sales performance [5] - **Management Expenses**: Management expenses fell by 28.09% to 112,695,669.98 yuan, reflecting successful cost reduction measures [6] - **Financial Expenses**: Financial expenses remained stable at 40,282,025.19 yuan, indicating ongoing debt pressure, with a notable bond balance of 185 million yuan due [7] Cash Flow Analysis - **Operating Cash Flow**: The net cash flow from operating activities turned negative at -5,550,958.03 yuan, down 115.83% from 35,063,943.44 yuan in 2023, indicating weakened cash generation ability [10] - **Investing Cash Flow**: The net cash flow from investing activities was positive at 64,489,461.03 yuan, a recovery from -9,366,822.30 yuan in 2023, primarily due to asset disposals [11] - **Financing Cash Flow**: The net cash flow from financing activities improved to -10,724,112.52 yuan from -192,978,032.40 yuan in 2023, reflecting a need for improved financing conditions [12] Overall Assessment - Despite achieving a net profit turnaround, the company faces challenges with declining revenue, deteriorating cash flow, and reduced R&D investment, which may impact future growth potential. Investors should closely monitor the company's restructuring process, market strategy adjustments, and cost control efforts to assess investment value and risks [1]